Suppr超能文献

雾化吸入的乙磺半胱氨酸戊烷脒的肺部沉积:雾化器类型、剂量和填充体积的影响。

Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill.

作者信息

O'Doherty M, Thomas S, Page C, Bradbeer C, Nunan T, Bateman N

机构信息

Department of Nuclear Medicine, St Thomas's Hospital, London.

出版信息

Thorax. 1990 Jun;45(6):460-4. doi: 10.1136/thx.45.6.460.

Abstract

An estimate of the absolute pulmonary deposition of nebulised pentamidine isethionate was obtained in nine patients with AIDS. Two nebuliser systems were compared, System 22 Mizer (Medic-Aid) and Respirgard II (Marquest), with 50 and 150 mg doses of pentamidine in a 3 ml solution driven by an air flow of 6 l/min with the patient in the sitting position. The 50 mg pentamidine dose was repeated with a 6 ml fill with both devices. The nebuliser cloud was labelled with technetium-99m human serum albumin (Ventocol) and lung deposition was measured with a gamma camera. Of the two nebulisers studied, System 22 Mizer delivered more drug to the lungs as a whole and to each individual lung region, including the peripheral and upper zones. For the 50 mg dose the mean (SEM) total pulmonary deposition with the 3 and the 6 ml fill respectively was 2.63 (0.34) and 3.71 (0.41) mg for the System 22 Mizer and 1.37 (0.26) and 1.45 (0.18) mg for the Respirgard II. For the 150 mg dose the System 22 Mizer delivered 7.16 (1.02) mg and the Respirgard II 4.34 (0.57) mg. Increasing the volume of fill from 3 to 6 ml increased pulmonary deposition with System 22 Mizer, and this was related to an increase in nebuliser output. Neither pulmonary deposition nor nebuliser output was increased by using a 6 ml solution in the Respirgard II. Increasing the volume of fill prolonged the time required for nebulisation with both nebulisers. The System 22 Mizer produced more nonpulmonary (gastric and oropharyngeal) deposition of drug, more frequent local adverse effects (cough, burning in the throat, and a metallic taste), and small reductions in lung function, particularly with the 150 mg pentamidine dose. Thus nebuliser type, volume of fill, and nebuliser dose affect the pulmonary deposition of pentamidine. A 300 mg dose of pentamidine via a Respirgard II is generally recommended as providing effective prophylaxis; our results suggest that similar pulmonary deposition can be produced with System 22 Mizer and 150 mg pentamidine. A clinical trial would be needed to show whether this regimen provides similar prophylactic benefit.

摘要

对9例艾滋病患者雾化吸入的乙磺半胱氨酸戊烷脒的绝对肺沉积量进行了估计。比较了两种雾化器系统,即22型米泽雾化器(Medic-Aid公司)和Respirgard II雾化器(Marquest公司),患者取坐位,在6升/分钟的气流驱动下,用3毫升溶液分别雾化50毫克和150毫克的戊烷脒。两种装置均用6毫升溶液重复雾化50毫克戊烷脒。雾化器喷出的雾滴用锝-99m人血清白蛋白(Ventocol)标记,并用γ相机测量肺部沉积量。在所研究的两种雾化器中,22型米泽雾化器总体上以及在每个肺区域(包括外周和上部区域)向肺部输送的药物更多。对于50毫克剂量,22型米泽雾化器3毫升和6毫升填充量时的平均(标准误)总肺沉积量分别为2.63(0.34)毫克和3.71(0.41)毫克,Respirgard II雾化器分别为1.37(0.26)毫克和1.45(0.18)毫克。对于150毫克剂量,22型米泽雾化器输送7.16(1.02)毫克,Respirgard II雾化器输送4.34(0.57)毫克。22型米泽雾化器将填充量从3毫升增加到6毫升可增加肺沉积量,这与雾化器输出量增加有关。在Respirgard II雾化器中使用6毫升溶液既未增加肺沉积量也未增加雾化器输出量。增加填充量会延长两种雾化器的雾化时间。22型米泽雾化器产生的药物非肺部(胃和口咽)沉积更多,局部不良反应(咳嗽、喉咙烧灼感和金属味)更频繁,肺功能有小幅下降,尤其是在使用150毫克戊烷脒剂量时。因此,雾化器类型、填充量和雾化剂量会影响戊烷脒的肺沉积量。一般推荐通过Respirgard II雾化器使用300毫克戊烷脒剂量以提供有效的预防;我们的结果表明,使用22型米泽雾化器和150毫克戊烷脒可产生相似的肺沉积量。需要进行临床试验以表明该方案是否能提供相似的预防益处。

相似文献

引用本文的文献

2
The science of nebulised drug delivery.雾化药物递送科学。
Thorax. 1997 Apr;52 Suppl 2(Suppl 2):S31-44. doi: 10.1136/thx.52.2008.s31.
4
Pulmonary deposition of a nebulised aerosol during mechanical ventilation.
Thorax. 1993 Feb;48(2):154-9. doi: 10.1136/thx.48.2.154.
6
Aerosols for therapy and diagnosis.用于治疗和诊断的气雾剂。
Eur J Nucl Med. 1993 Dec;20(12):1201-13. doi: 10.1007/BF00171019.
7
Antibiotic penetration into lung tissues.抗生素在肺组织中的渗透。
Thorax. 1994 Feb;49(2):104-6. doi: 10.1136/thx.49.2.104.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验